University of Chicago Medicine Orland Park
Orland Park, IL
Not currently accepting
Cirtuvivint
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 and ASTX727 + Venetoclax in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
- Tyrosine Kinase (TK) Inhibitor
- Dual Specificity TK Inhibitor (DYRK)
- CLK Inhibitor
- Phase 1